Central Nervous System News and Research

RSS

Arena's NDA receives Complete Response Letter for lorcaserin

Arena Pharmaceuticals, Inc. and Eisai Inc. announced that the US Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding Arena's New Drug Application (NDA) for lorcaserin. Lorcaserin is intended for weight management, including weight loss and maintenance of weight loss, in patients who are obese

25 Oct 2010

Scientists discover new cell that may limit inflammation in CNS

Scientists at Barrow Neurological Institute have recently made discoveries about a type of cell that may limit inflammation in the central nervous system - a finding that could have important implications in the treatment of brain disorders such as multiple sclerosis. The research, led by Barrow's Fu-Dong Shi, MD, PhD, was published in the August 2010 issue of The Journal of Experimental Medicine, and simultaneously highlighted in Nature.

22 Oct 2010

ISCTM to develop solutions for CNS clinical trial methodology

The International Society for CNS Clinical Trials and Methodology (ISCTM) met recently to develop solutions to challenges facing CNS clinical trial methodology.

21 Oct 2010

Joint stem cell study to investigate multiple sclerosis

A $2.2 million project by Victorian and Californian researchers will assess whether stem cell therapies can be used to combat diseases such as Multiple Sclerosis and Type-1 diabetes, and help organ transplant recipients. Speaking at AusBiotech 2010 in Melbourne today, Innovation Minister Gavin Jennings said the Brumby Labor Government had contributed $575,505 to the project, the fifth to be funded through the $28 million Victoria–California Stem Cell Alliance which was established in 2008 under the Biotechnology Strategic Development Plan.

21 Oct 2010

Arena reports results of APD916 Phase 1 clinical trial for narcolepsy with cataplexy

Arena Pharmaceuticals, Inc. announced today results from a Phase 1 clinical trial of APD916, a novel drug candidate discovered by Arena that targets the histamine H3 receptor for the treatment of narcolepsy with cataplexy.

20 Oct 2010

Envoy expands drug discovery collaboration with The Scripps Research Institute

Envoy Therapeutics, Inc., a recently-formed drug discovery company, today announced that it has expanded its research collaboration with The Scripps Research Institute aimed at identifying new drugs for neurological and psychiatric diseases.

20 Oct 2010

Pfizer enters partnership with Teuto to develop, commercialize generic medicines

Pfizer Inc. announced today that it is entering into a partnership with Laboratorio Teuto Brasileiro S.A., a leading company in the Brazilian generics industry, to develop and commercialize generic medicines.

20 Oct 2010

Study finds massive blood transfusion associated with severe complications

A study presented at this year's American Society of Anesthesiologists Annual Meeting indicates that massive blood transfusion is associated with a significant increase in perioperative risk for mortality, cardiopulmonary complications, and wound-related and infectious complications in the long term.

20 Oct 2010

Rexahn announces publication of 3-aryl-1-isoquinolinamines preclinical data

Rexahn Pharmaceuticals, Inc. a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced the publication of new preclinical data on the development of 3-aryl-1-isoquinolinamines in the European Journal & Medicinal Chemistry.

19 Oct 2010

Pseudobulbar affect impacts majority of stroke survivors, but few have any understanding of condition

A survey released today by National Stroke Association shows that 53 percent of stroke survivor respondents suffer from symptoms of another neurologic condition called pseudobulbar affect (PBA), a condition thought to be caused by structural damage in the brain due to injury or disease. PBA causes involuntary and unpredictable outbursts of laughing or crying, often in socially inappropriate situations. Even though a significant proportion of stroke survivors suffer from PBA, fewer than one in five are familiar with the condition.

19 Oct 2010

STOP-BANG questionnaire on sleep apnea syndrome helps identify patients' risk for surgical complication

A research team from the Jefferson Sleep Disorders Center at Thomas Jefferson University Hospital has utilized a simple, eight-item pre-operative questionnaire about obstructive sleep apnea syndrome that could help identify patients at risk for complications following surgery, according to a report in the October issue of Archives of Otolaryngology-Head & Neck Surgery, one of the JAMA/Archives journals. Individuals prone to the obstructive sleep apnea syndrome as determined by the questionnaire appear to have an increased risk of heart, lung and other complications following elective surgery.

19 Oct 2010

Somaxon announces nonreceipt of Paragraph IV certification for generic Silenor ANDA

Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that the website of the U.S. Food and Drug Administration (FDA) indicates that an Abbreviated New Drug Application (ANDA) for a generic version of Silenor® (doxepin) 3 mg and 6 mg was submitted on September 16, 2010.

19 Oct 2010

Nektar presents data of NKTR-181 mu-opioid analgesic candidate at Pain 2010 Symposium

Nektar Therapeutics presented promising data today from preclinical studies of NKTR-181, a next-generation mu-opioid analgesic candidate with a novel molecular design. NKTR-181 is being developed to effectively treat pain while addressing the abuse liability and serious side effects associated with traditional opioid therapies.

18 Oct 2010

Major advance in treatment of brain disorders with external genes

In the October 17 issue of Nature Methods, researchers at Thomas Jefferson University describe how they can transfer genes into brain neurons intravenously, using a viral gene delivery vehicle (vector) that causes no side effects.

18 Oct 2010

Nektar presents NKTR-181 preclinical data at ASA 2010 Annual Meeting

Nektar Therapeutics today presented new preclinical data demonstrating that NKTR-181, a mu-opioid analgesic with a novel molecular structure, dramatically reduces abuse liability while providing analgesia comparable to oxycodone and morphine.

18 Oct 2010

Neuroprotective properties of laquinimod for RRMS presented at 26th ECTRIMS Congress

Teva Pharmaceutical Industries Ltd. and Active Biotech announced today that data providing further evidence of the neuroprotective properties of laquinimod in animal studies were presented at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Gothenburg, Sweden.

15 Oct 2010

Questcor, CNF partner to fund infantile spasms research

Questcor Pharmaceuticals, Inc. announced that it is partnering with the Child Neurology Foundation (CNF) to fund a $30,000 grant to support research into infantile spasms (IS). Catherine Chu-Shore, MD, of Massachusetts General Hospital was selected by CNF as the recipient of this first-ever "Logan Infantile Spasms Research Award."

15 Oct 2010

Galenea awarded $4.5M NIMH grant to advance Multiwell, Automated NeuroTRansmission Assay platform

Galenea Corp. has been awarded a highly competitive grant from the National Institute of Mental Health in response to the solicitation "Recovery Act Limited Competition: NIH Director's Opportunity for Research in Five Thematic Areas (RC4)," funded by the American Recovery and Reinvestment Act of 2009. Galenea has developed an innovative technology platform, termed MANTRA™ (Multiwell, Automated NeuroTRansmission Assay) that enables high-throughput screening for the identification of small molecule modulators of synaptic transmission.

14 Oct 2010

Genmab and Lundbeck enter agreement to develop antibody therapeutics

Genmab A/S announced today an agreement to create and develop human antibody therapeutics for disorders of the central nervous system (CNS) with H. Lundbeck A/S. Genmab will create novel human antibodies to three targets identified by Lundbeck. Lundbeck will have access to Genmab's antibody creation and development capabilities, including its state of the art, fully automated pre-clinical antibody screening and characterization capabilities and its proprietary stabilized IgG4 and UniBody therapeutic antibody platforms.

13 Oct 2010

Lundbeck, Merck announce commercialization agreement for SYCREST sublingual tablets

H. Lundbeck A/S (Lundbeck) and Merck, known outside the United States and Canada as MSD, today announced a commercialization agreement for SYCREST (asenapine) sublingual tablets (5 mg, 10 mg). Under the terms of the agreement, Lundbeck will pay an undisclosed fee as well as product supply payments in exchange for exclusive commercial rights to SYCREST in all markets outside the United States, China and Japan. Lundbeck expects to launch SYCREST in the European Union (EU), where it is already approved, at the beginning of 2011.

12 Oct 2010

Central Nervous System News and Research

Arena's NDA receives Complete Response Letter for lorcaserin

Scientists discover new cell that may limit inflammation in CNS

ISCTM to develop solutions for CNS clinical trial methodology

Joint stem cell study to investigate multiple sclerosis

Arena reports results of APD916 Phase 1 clinical trial for narcolepsy with cataplexy

Envoy expands drug discovery collaboration with The Scripps Research Institute

Pfizer enters partnership with Teuto to develop, commercialize generic medicines

Study finds massive blood transfusion associated with severe complications

Rexahn announces publication of 3-aryl-1-isoquinolinamines preclinical data

Pseudobulbar affect impacts majority of stroke survivors, but few have any understanding of condition

STOP-BANG questionnaire on sleep apnea syndrome helps identify patients' risk for surgical complication

Somaxon announces nonreceipt of Paragraph IV certification for generic Silenor ANDA

Nektar presents data of NKTR-181 mu-opioid analgesic candidate at Pain 2010 Symposium

Major advance in treatment of brain disorders with external genes

Nektar presents NKTR-181 preclinical data at ASA 2010 Annual Meeting

Neuroprotective properties of laquinimod for RRMS presented at 26th ECTRIMS Congress

Questcor, CNF partner to fund infantile spasms research

Galenea awarded $4.5M NIMH grant to advance Multiwell, Automated NeuroTRansmission Assay platform

Genmab and Lundbeck enter agreement to develop antibody therapeutics

Lundbeck, Merck announce commercialization agreement for SYCREST sublingual tablets

Event guide: The 7th CNS Drug Delivery Summit eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News